June 27, 2016
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, […]
News and analysis articles with a focus on Mergers, Partnerships & Acquisitions within the Biotechnology, Biopharmaceutical, Informatics, Analytics and related industries.
June 20, 2016
Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology […]
May 31, 2016
Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company […]
May 24, 2016
Last week German multinational Bayer put forward an all-cash $62B bid for American AgTech giant Monsanto, further emphasizing the unprecedented period of consolidation that the global […]
May 18, 2016
Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcel™, its promising cardiac regeneration medicine. Under the conditions of […]
March 17, 2016
A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for […]
February 11, 2016
China made its boldest overseas takeover move yet this week, announcing that state-owned company ChemChina has submitted a $43 billion bid for Swiss seeds and pesticides […]
January 27, 2016
Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) […]
January 12, 2016
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously […]